NSCC Update

[Rich Klein]

This is from the Politico Newsletter this morning. Politico is reasonably well centered in how they report about Washington (they try to keep down the middle as much as possible)

- STAT: "Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment," by Adam Feurstein and Matthew Herper: "A Chicago hospital treating severe Covid-19 patients with Gilead Sciences' antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.

"Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead's clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.

"The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead's two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir

That's why David was talking about stuff moving overnight. I have no dog in this fight but he follows the market a lot closer than I do and this could be an important development.

Rich